When IV therapy is prescribed, most patients assume medication is delivered the same way every time,through a vein via an IV catheter. In reality, several specialty therapies can be administered through two distinct routes: intravenous (IV) or subcutaneous (sub-Q). Understanding the difference between these delivery methods helps patients and caregivers prepare for treatment and ask better questions of their care team.
Pharmko provides both IV and subcutaneous therapies as part of our
home infusion services, and our clinical team guides every patient through the right approach for their specific prescription.
What Is Intravenous (IV) Infusion?
Intravenous infusion delivers medication directly into the bloodstream through a vein. This is typically done via a peripheral IV line, a PICC line, or a central venous catheter, depending on the therapy, the patient's vascular access, and the duration of treatment.
IV infusion is used when:
- The medication requires rapid, complete absorption into the bloodstream
- The dose is too large or the formulation too concentrated for subcutaneous delivery
- The therapy must run over a specific, controlled time window (2–8 hours)
- Frequent or ongoing IV access is already in place
Common IV therapies include IV antibiotics, IVIG (intravenous immunoglobulin), TPN, Remicade, and Milrinone.
What Is Subcutaneous (Sub-Q) Infusion?
Subcutaneous infusion delivers medication into the tissue just beneath the skin,not into a vein. A small needle or soft cannula is inserted at an angle, typically in the abdomen, thigh, or upper arm, and medication is infused slowly over a shorter or longer period depending on the therapy.
Sub-Q delivery is used when:
- The medication is formulated for subcutaneous absorption
- The patient benefits from more frequent, smaller-volume doses
- Vascular access is difficult or limited
- The patient or caregiver can be trained for independent self-administration
SCIG vs IVIG: The Most Common Subcutaneous Option
The most widely used subcutaneous infusion therapy in home settings is subcutaneous immunoglobulin (SCIG),an alternative to intravenous immunoglobulin (IVIG) for patients with primary immune deficiencies and certain neurological conditions.
Key differences between SCIG and IVIG:
- Frequency: SCIG is typically given weekly or biweekly in smaller doses; IVIG is given every 3–4 weeks in larger doses
- Administration site: SCIG uses subcutaneous tissue; IVIG uses venous access
- Setting: SCIG is often self-administered at home after training; IVIG typically requires a nurse present for the infusion
- Side effect profile: SCIG is associated with fewer systemic reactions than IVIG, though local site reactions (redness, swelling) are more common
Your immunologist or neurologist will determine which route is appropriate based on your diagnosis, antibody levels, lifestyle, and vascular access. Not all patients are candidates for SCIG.
Which Route Is Right for Your Therapy?
The choice between IV and subcutaneous delivery is determined by the medication itself, not patient preference alone. Most specialty medications are formulated for a specific route,you cannot substitute subcutaneous delivery for IV administration unless your prescribing physician and pharmacist confirm the medication is approved for both.
Factors your care team will consider:
- The specific drug and its approved administration routes
- Your diagnosis and clinical goals
- Your vascular access history and current access options
- Your ability to self-administer or the availability of caregiver support
- Your insurance coverage and prior authorization requirements
What to Expect at Home
Whether your therapy is IV or subcutaneous, Pharmko provides full clinical support from first dose through the end of treatment. Our nurses train patients and caregivers on proper technique, site care, and what to watch for. Know
which symptoms should prompt a call regardless of your delivery route,reactions can occur with both IV and sub-Q therapies.
Insurance coverage for subcutaneous therapies varies by plan and diagnosis. Pharmko's team handles prior authorization and coordinates coverage verification before your first delivery.
→
Contact Pharmko to discuss your therapy options: 1-877-540-2003
